German pharmaceutical company BioNTech confirmed this Wednesday that it has started testing a possible coronavirus vaccine in volunteers.
The 12 participants in the clinical trial conducted in Germany received doses of the BNT162 vaccine since April 23, explained BioNTech, a company that works with the U.S. Pfizer.
Several pharmaceutical companies are in the race to find a vaccine against the SARS-CoV-2 virus that has caused a pandemic, leaving more than 215,000 dead and infecting at least three million people.
In the next phase of the trial, which will involve about 200 people between the ages of 18 and 55, the dose of the drug will start being increased, BioNTech said in a statement.
The company said it expects to receive authorization from the regulator to start trials in the United States soon.